More information: Ferdinandos Skoulidis et al, Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer, Nature Medicine (2025). DOI: 10.1038/s41591-025 ...

Real-world patient data from June 2021 through February 2023 show that among a cohort of 128 patients who received the KRAS inhibitor sotorasib for their KRAS G12C–mutated non–small cell lung ...

The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...

FGTI-2734 and sotorasib are synergistic at inhibiting the viability of sotorasib-resistant (Calu-1 and LU99) and sotorasib-sensitive (H2122 and H358) human KRAS G12C lung cancer cells.

Sotorasib targets the KRAS G12C protein specifically and is the first KRAS G12C inhibitor to be FDA-approved for clinical use. It works by binding to the mutated KRAS G12C protein, blocking its ...

Sotorasib Promising for KRAS–Related Vascular Malformations — Two patients had rapid symptom improvement and reductions in malformation volume by Mike Bassett , Staff Writer, MedPage Today ...

In contrast for the US, sotorasib led to 0.35 more QALYs compared with docetaxel, at an ICER of $15,976.50/QALY, and a total between 1 and 3 times the GDP, “indicating that the increased cost of ...

Key takeaways: The FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer.; The agency also approved acalabrutinib as part of combination therapy for mantle cell lymphoma.